What was the overall market valuation of the US sciatica market in 2024?

The overall market valuation was $158.39 Million in 2024. Read More

What is the projected market valuation for the US sciatica market by 2035?

The projected valuation for 2035 is $270.83 Million. Read More

What is the expected CAGR for the US sciatica market during the forecast period 2025 - 2035?

The expected CAGR for the US sciatica market during the forecast period 2025 - 2035 is 5.0%. Read More

Which companies are considered key players in the US sciatica market?

Key players in the market include Medtronic, Johnson & Johnson, Stryker, Boston Scientific, NuVasive, DePuy Synthes, Abbott Laboratories, and Globus Medical. Read More

What are the segment valuations for L4, L5, and S1 nerve root sciatica?

The segment valuations are $30.0 - $50.0 Million for L4, $40.0 - $70.0 Million for L5, and $50.0 - $90.0 Million for S1 nerve root sciatica. Read More

How do pain killers compare to other drug segments in the US sciatica market?

Pain killers have a valuation range of $63.36 - $108.34 Million, which is higher than other drug segments like muscle relaxants and antidepressants. Read More

What is the valuation range for non-drug treatments like physiotherapy and surgery?

Physiotherapy is valued at $40.0 - $70.0 Million, while surgery has a valuation range of $50.0 - $80.0 Million. Read More

What are the primary end users in the US sciatica market?

Primary end users include hospitals and clinics, valued at $70.0 - $120.0 Million, and research and academics, valued at $40.0 - $70.0 Million. Read More

What is the valuation range for anesthetics in the drug segment?

Anesthetics have a valuation range of $15.84 - $27.08 Million in the drug segment. Read More

How does the market for other non-drug treatments compare to acupuncture and stimulation devices?

Other non-drug treatments are valued at $13.39 - $25.83 Million, which is lower than acupuncture at $30.0 - $50.0 Million and stimulation devices at $25.0 - $45.0 Million. Read More

US Sciatica Market

ID: MRFR/Pharma/11472-CR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Sciatica Market Research Report Information: By Type (L4, L5, S1), Drug Treatment (Anesthetic, Pain Killer, Muscle Relaxant, Antidepressant, Steroid), Non-Drug Treatment (Physiotherapy, Acupuncture, Stimulation Device), End User (Hospital) - Forecast Till 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Type (USD Million)
  1. 4.1.1 L4 nerve root sciatica
  2. 4.1.2 L5 nerve root sciatica
  3. 4.1.3 S1 nerve root sciatica
  4. 4.1.4 others
2. 4.2 Pharmaceutical, BY Drugs (USD Million)
  1. 4.2.1 anesthetics
  2. 4.2.2 pain killers
  3. 4.2.3 muscle relaxants
  4. 4.2.4 antidepressants
  5. 4.2.5 steroids
  6. 4.2.6 others
3. 4.3 Pharmaceutical, BY Non-Drug Treatment (USD Million)
  1. 4.3.1 physiotherapy
  2. 4.3.2 acupuncture
  3. 4.3.3 stimulation devices
  4. 4.3.4 surgery
  5. 4.3.5 others
4. 4.4 Pharmaceutical, BY End User (USD Million)
  1. 4.4.1 hospitals and clinics
  2. 4.4.2 research and academics
  3. 4.4.3 others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Medtronic (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Johnson & Johnson (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Stryker (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Boston Scientific (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 NuVasive (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 DePuy Synthes (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Abbott Laboratories (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Globus Medical (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DRUGS
4. 6.4 US MARKET ANALYSIS BY NON-DRUG TREATMENT
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY DRUGS, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY DRUGS, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY NON-DRUG TREATMENT, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY NON-DRUG TREATMENT, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DRUGS, 2025-2035 (USD Million)
  3. 7.2.3 BY NON-DRUG TREATMENT, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Pharmaceutical Market Segmentation

Pharmaceutical By Type (USD Million, 2025-2035)

L4 nerve root sciatica
L5 nerve root sciatica
S1 nerve root sciatica
others

Pharmaceutical By Drugs (USD Million, 2025-2035)

anesthetics
pain killers
muscle relaxants
antidepressants
steroids
others

Pharmaceutical By Non-Drug Treatment (USD Million, 2025-2035)

physiotherapy
acupuncture
stimulation devices
surgery
others

Pharmaceutical By End User (USD Million, 2025-2035)

hospitals and clinics
research and academics
others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”